Answers are grounded in this paper and cite their sources.
Demonstrates that inhibiting protein kinase C beta improves survival and suppresses inflammatory signaling in murine lung ischemia-reperfusion injury, highlighting a potential therapeutic target.
Activation of PKCII is associated with the response to ischemia/reperfusion (I/R), though its role, either pathogenic or protective, has not been determined. In a murine model of single-lung I/R, evidence linking PKC to maladaptive responses is shown in the following studies. Homozygous PKC-null mice and WT mice fed the PKC inhibitor ruboxistaurin subjected to I/R displayed increased survival compared with controls. In PKC-null mice, phosphorylation of extracellular signal-regulated protein kinase-1 and -2 (ERK1/2), JNK, and p38 MAPK was suppressed in I/R. Expression of the immediate early gene, early growth response-1 (Egr-1), and its downstream target genes was significantly increased in WT mice in I/R, particularly in mononuclear phagocytes (MPs), whereas this expression was attenuated in PKC-null mice or WT mice fed ruboxistaurin. In vitro, hypoxia/reoxygenation-mediated induction of Egr-1 in MPs was suppressed by inhibition of PKC, ERK1/2, and JNK, but not by inhibition of p38 MAPK. These findings elucidate key roles for PKCII activation in I/R by coordinated activation of MAPKs (ERK1/2, JNK) and Egr-1.
No takes yet. Share an insight, caveat, or question.
Fujita et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: